The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Gene therapy clinical trials, where do we go? An overview
Open accessAbstract
There have been many ups and downs since the introduction of gene therapy as a therapeutic modality for diseases. However, the journey of gene therapy has reached a fundamental milestone, as evidenced by the increasing number of gene therapy products on the market. Looking at the currently approved and under-approval products, as well as the numerous clinical trials in this field, gene therapy has a promising future. Trend of changes in gene therapy strategies, vectors, and targets could be insightful for pharmaceutical companies, policymakers, and researchers. In this paper, following a brief history of gene therapy, we reviewed current gene therapy products as well as gene therapies that may be approved in the near future. We also looked at ten-year changes in gene therapy clinical trials strategies, such as the use of vectors, target cells, transferred genes, and ex-vivo/in-vivo methods, as well as the major fields that gene therapy has entered. Although gene therapy was initially used to treat genetic diseases, cancer now has the greatest number of gene therapy clinical trials. Changes in gene therapy strategies, particularly in pioneering countries in this field, may point to the direction of future clinical products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171737a0 · Cited by 13,584
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Global Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
Research works printed but not linked: 79
- Anderson, 1990, September 14, 1990: the beginning, Hum. Gene Ther., 1, 371, 10.1089/hum.1990.1.4-371 · doi:10.1089/hum.1990.1.4-371
- Portin, 2017, The evolving definition of the term “gene”, Genetics, 205, 1353, 10.1534/genetics.116.196956 · DOI
- Wolff, 1994, An early history of gene transfer and therapy, Hum. Gene Ther., 5, 469, 10.1089/hum.1994.5.4-469 · DOI
- Arber, 1969, DNA modification and restriction, Annu. Rev. Biochem., 38, 467, 10.1146/annurev.bi.38.070169.002343 · DOI · Paper page
- Lehman, 1974, DNA ligase: structure, mechanism, and function, Science, 186, 790, 10.1126/science.186.4166.790 · DOI · Paper page
- Friedmann, 1992, A brief history of gene therapy, Nat. Genet., 2, 93, 10.1038/ng1092-93 · DOI · Paper page
- Mulligan, 1993, The basic science of gene therapy, Science, 260, 926, 10.1126/science.8493530 · DOI · Paper page
- Williams, 1984, Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse, Nature, 310, 476, 10.1038/310476a0 · DOI · Paper page
- Merrouche, 1995, Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 13, 410, 10.1200/JCO.1995.13.2.410 · DOI
- Blaese, 1995, T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475 · DOI · Paper page
- King, 2017, New treatments for serious conditions: ethical implications, Gene Ther., 24, 534, 10.1038/gt.2017.32 · doi:10.1038/gt.2017.32
- Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669 · DOI · Paper page
- Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin. Investig., 118, 3143, 10.1172/JCI35798 · DOI · Paper page
- Zhang, 2018, The first approved gene therapy product for cancer Ad-p53 (gendicine): 12 years in the clinic, Hum. Gene Ther., 29, 160, 10.1089/hum.2017.218 · DOI · Paper page
- Liang, 2018, Oncorine, the world first oncolytic virus medicine and its update in China, Curr. Cancer Drug Targets, 18, 171, 10.2174/1568009618666171129221503 · DOI · Paper page
- Gruber, 2012, Europe gives gene therapy the green light, Lancet, 380, 10.1016/S0140-6736(12)61992-8 · DOI
- Padhy, 2020, Voretigene neparvovec and gene therapy for leber’s congenital amaurosis: review of evidence to date, Appl. Clin. Genet., 13, 179, 10.2147/TACG.S230720 · DOI
- Mahajan, 2019, Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever, Int. J. Appl. Basic Med. Res., 9, 127, 10.4103/ijabmr.IJABMR_190_19 · DOI
- Shahryari, 2019, Development and clinical translation of approved gene therapy products for genetic disorders, Front. Genet., 10, 868, 10.3389/fgene.2019.00868 · DOI · Paper page
- Ma, 2020, The approved gene therapy drugs worldwide: from 1998 to 2019, Biotechnol. Adv., 40, 10.1016/j.biotechadv.2019.107502 · DOI · Paper page
- Anguela, 2019, Entering the modern era of gene therapy, Annu. Rev. Med., 70, 273, 10.1146/annurev-med-012017-043332 · DOI · Paper page
- Batty, 2019, Advances and challenges for hemophilia gene therapy, Hum. Mol. Genet., 28, R95, 10.1093/hmg/ddz157 · DOI
- Zarogoulidis, 2013, Suicide gene therapy for cancer - current strategies, J. Genet. Syndr. Gene Ther., 4, 16849
- Nakagami, 2021, Development of COVID-19 vaccines utilizing gene therapy technology, Int. Immunol., 33, 521, 10.1093/intimm/dxab013 · DOI
- Chow, 2018, Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma, Blood, 132, 777, 10.1182/blood-2018-04-839217 · DOI
- Mitrpant, 2013, Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy, PLoS One, 8, 10.1371/journal.pone.0062114 · DOI
- Uddin, 2020, CRISPR gene therapy: applications, limitations, and implications for the future, Front. Oncol., 10, 1387, 10.3389/fonc.2020.01387 · DOI · Paper page
- Maurer, 2018, Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N. Engl. J. Med., 379, 1007, 10.1056/NEJMoa1805689 · DOI · Paper page
- Bulaklak, 2020, The once and future gene therapy, Nat. Commun., 11, 5820, 10.1038/s41467-020-19505-2 · DOI · Paper page
- Junghans, 2017, The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective, Cancer Gene Ther., 24, 89, 10.1038/cgt.2016.82 · DOI
- Xu, 2019, Generation of CAR-T cells for cancer immunotherapy, Methods Mol. Biol., 1884, 349, 10.1007/978-1-4939-8885-3_24 · DOI
- Mansouri, 2021, Recent advances in regenerative medicine strategies for cancer treatment, Biomed. Pharmacother., 141, 10.1016/j.biopha.2021.111875 · DOI
- Jayaraman, 2020, CAR-T design: elements and their synergistic function, EBioMedicine, 58, 10.1016/j.ebiom.2020.102931 · DOI · Paper page
- Tokarew, 2019, Teaching an old dog new tricks: next-generation CAR T cells, Br. J. Cancer, 120, 26, 10.1038/s41416-018-0325-1 · DOI · Paper page
- Zhao, 2021, Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons, Front. Immunol., 12
- Fu, 2020, DC-based vaccines for cancer immunotherapy, Vaccines, 706, 10.3390/vaccines8040706 · DOI
- Bouard, 2009, Viral vectors: from virology to transgene expression, Br. J. Pharmacol., 157, 153, 10.1038/bjp.2008.349 · DOI · Paper page
- Goswami, 2019, Gene therapy leaves a vicious cycle, Front. Oncol., 9, 297, 10.3389/fonc.2019.00297 · DOI · Paper page
- Ghosh, 2020, Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges, Appl. Biosaf., 25, 7, 10.1177/1535676019899502 · DOI · Paper page
- Ura, 2014, Developments in viral vector-based vaccines, Vaccines, 624, 10.3390/vaccines2030624 · DOI · Paper page
- Bulcha, 2021, Viral vector platforms within the gene therapy landscape, Signal Transduct. Target. Ther., 6, 53, 10.1038/s41392-021-00487-6 · DOI · Paper page
- Labbe, 2021, Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives, Viruses, 13, 1528, 10.3390/v13081528 · DOI
- Gao, 2020, Expanding the spectrum of adenoviral vectors for cancer therapy, Cancers, 1139, 10.3390/cancers12051139 · DOI
- Gao, 2019, State-of-the-art human adenovirus vectorology for therapeutic approaches, FEBS Lett., 593, 3609, 10.1002/1873-3468.13691 · DOI
- Sainz-Ramos, 2021, How far are non-viral vectors to come of age and reach clinical translation in gene therapy?, Int. J. Mol. Sci., 22, 7545, 10.3390/ijms22147545 · DOI
- Chira, 2015, Progresses towards safe and efficient gene therapy vectors, Oncotarget, 6, 30675, 10.18632/oncotarget.5169 · DOI · Paper page
- Jafarlou, 2016, An overview of the history, applications, advantages, disadvantages and prospects of gene therapy, J. Biol. Regul. Homeost. Agents, 30, 315
- Razi Soofiyani, 2013, Gene therapy, early promises, subsequent problems, and recent breakthroughs, Adv. Pharm. Bull., 3, 249
- Selkirk, 2004, Gene therapy in clinical medicine, Postgrad. Med. J., 80, 560, 10.1136/pgmj.2003.017764 · DOI
- Stein, 2017, FDA-approved oligonucleotide therapies in 2017, Mol. Ther., 25, 1069, 10.1016/j.ymthe.2017.03.023 · DOI · Paper page
- Guo, 2018, Development of gene therapeutics for head and neck cancer in China: from bench to bedside, Hum. Gene Ther., 29, 180, 10.1089/hum.2017.230 · DOI
- Pearson, 2004
- Gordon, 2009, The ‘timely’development of Rexin-G: first targeted injectable gene vector, Int. J. Oncol., 35, 229
- Ylä-Herttuala, 2012, Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union, Mol. Ther., 20, 1831, 10.1038/mt.2012.194 · DOI · Paper page
- Poh, 2016, First oncolytic viral therapy for melanoma, Cancer Discov., 6, 6, 10.1158/2159-8290.CD-NB2015-158 · DOI
- Ott, 2016, Talimogene laherparepvec for the treatment of advanced melanoma, Clin. Cancer Res., 22, 3127, 10.1158/1078-0432.CCR-15-2709 · DOI
- Farkas, 2017, Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe, Front. Med, 4, 53, 10.3389/fmed.2017.00053 · DOI
- Hoggatt, 2016, Gene therapy for “Bubble Boy” disease, Cell, 166, 263, 10.1016/j.cell.2016.06.049 · DOI
- Schimmer, 2016, Investor outlook: rising from the ashes; GSK’s European Approval of Strimvelis for ADA-SCID, Hum. Gene Ther. Clin. Dev., 27, 57, 10.1089/humc.2016.29010.ind · DOI
- Stirnadel-Farrant, 2018, Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID, Orphanet J. Rare Dis., 13, 49, 10.1186/s13023-018-0791-9 · DOI
- Aartsma-Rus, 2019, A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe, Nucleic Acid. Ther., 29, 13, 10.1089/nat.2018.0756 · DOI
- Korinthenberg, 2019, A new era in the management of Duchenne muscular dystrophy, Dev. Med. Child Neurol., 61, 292, 10.1111/dmcn.14129 · DOI
- Ottesen, 2017, ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy, Transl. Neurosci., 8, 1, 10.1515/tnsci-2017-0001 · DOI · Paper page
- Russell, 2017, Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial, Lancet, 390, 849, 10.1016/S0140-6736(17)31868-8 · DOI · Paper page
- Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
- Evans, 2018, Arthritis gene therapy is becoming a reality, Nat. Rev. Rheumatol., 14, 381, 10.1038/s41584-018-0009-5 · DOI
- Evans, 2018, Arthritis gene therapy approved in Korea, J. Am. Acad. Orthop. Surg., 26, e36, 10.5435/JAAOS-D-17-00695 · DOI
- Gales, 2019, Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis, Pharmaceuticals, 78, 10.3390/ph12020078 · DOI
- Suda, 2014, Beperminogene perplasmid for the treatment of critical limb ischemia, Expert Rev. Cardiovasc. Ther., 12, 1145, 10.1586/14779072.2014.955850 · DOI
- Hoy, 2019, Onasemnogene abeparvovec: first global approval, Drugs, 79, 1255, 10.1007/s40265-019-01162-5 · DOI · Paper page
- Y.A. Heo, Golodirsen: first approval, Drugs, 80, 2020, pp. 329–333. 〈10.1007/s40265-020-01267-2〉. · DOI · Paper page
- J. Paik, S. Duggan, Volanesorsen: first global approval, Drugs, 79, pp. 1349–1354. 〈10.1007/s40265-019-01168-z〉. · DOI · Paper page
- Y.N. Lamb, BNT162b2 mRNA COVID-19 vaccine: first approval, Drugs, 81, 2021, pp. 495–501. 〈10.1007/s40265-021-01480-7〉. · DOI · Paper page
- L.J. Scott, Givosiran: first approval, Drugs, 80, 2020, pp. 335–339. 〈10.1007/s40265-020-01269-0〉. · DOI · Paper page
- L.J. Scott, S.J. Keam, Lumasiran: first approval, Drugs, 81, 2021, pp. 277–282. 〈10.1007/s40265-020-01463-0〉. · DOI · Paper page
- Roshmi, 2021, Pharmacological profile of viltolarsen for the treatment of duchenne muscular dystrophy: a Japanese experience, Clin. Pharmacol., 13, 235
- Migliorati, 2022, siRNA drug Leqvio (inclisiran) to lower cholesterol, Trends Pharmacol. Sci., 43, 455, 10.1016/j.tips.2022.02.003 · DOI
- Ortiz-Maldonado, 2022, Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter’s transformation, Front. Oncol., 12, 10.3389/fonc.2022.828471 · DOI
- Press Release Daiichi Sankyo Launches DELYTACT ® Oncolytic Virus G47∆ in Japan. Available from: 〈www.daiichisankyo.com〉.
Cited by
Polyethylenimine (PEI) in gene therapy: Current status and clinical applications
Casper, J., Schenk, S. H., Parhizkar, E., Detampel, P., Dehshahri, A., & Huwyler, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.001 · Cited by 340
The paths and challenges of “off-the-shelf” CAR-T cell therapy: an overview of clinical trials
Moradi, V., Omidkhoda, A., & Ahmadbeigi, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115888 · Cited by 80
Self-citationManufacturing cell and gene therapies: challenges in clinical translation
Lee, N. K., & Chang, J. W. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0382 · Cited by 78
“In recent years, the demand for cell and gene therapy (CGT) has surged as the number of United States Food and Drug Administration (U.S. FDA)-approved CGT products has increased annually [1].”
BackgroundKoponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
Metadata
- Authors
- Arabi, F., Mansouri, V., & Ahmadbeigi, N.
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 153
- Pages
- 113324
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W4283778388
- Cited by
- 233
- References
- 15
- FWCI
- 28.00
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy clinical trials, where do we go? An overview. https://app.cochat.ai/papers/10.1016/j.biopha.2022.113324
- The paper
- Arabi, F., Mansouri, V., & Ahmadbeigi, N. (2022). Gene therapy clinical trials, where do we go? An overview. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2022.113324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.